Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Income from Continuing Operations of 37890000.0 for Q1 2026, up 211.47% on a QoQ basis from 12165000.0 in Q4 2025, and up 1322.65% year-over-year from 2663334.92 in Q1 2025.
Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 37890000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 1322.65% year-over-year to 37890000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124218000.0 (up 235.04% YoY) and the FY2025 annual result came in at 83229000.0, up 178.88% from the prior year.
- Income from Continuing Operations was 37890000.0 for Q1 2026 at Zevra Therapeutics, up from 12165000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 74707000.0 in Q2 2025 and bottomed at 35739000.0 in Q4 2024.
- A 5-year average of 2976294.12 and a median of 5700000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 674.39% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Income from Continuing Operations stood at 2972000.0 in 2022, then slumped by 569.31% to 19892000.0 in 2023, then plunged by 79.67% to 35739000.0 in 2024, then surged by 134.04% to 12165000.0 in 2025, then soared by 211.47% to 37890000.0 in 2026.
- Business Quant data shows ZVRA's Income from Continuing Operations at 37890000.0 in Q1 2026, 12165000.0 in Q4 2025, and 544000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -13.22 Mn |
| Dec 31, 2022 | -2.97 Mn |
| Sep 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -21.97 Mn |
| Mar 31, 2022 | 10.49 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | 6.20 Mn |